Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 2, 2004, Pages 135-147

  Milenic, Diane ^a   Garmestani, Kayhan ^a   Dadachova, Ekaterina ^a   Chappell, Lara ^a   Albert, Paul ^a   Hill, Donald ^a   Schlom, Jeffrey ^a   Brechbiel, Martin ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

particle; 213Bi; Bismuth; HuCC49 CH2; Radioimmunotherapy

Indexed keywords

BISMUTH 213; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BI 213; RADIOPHARMACEUTICAL AGENT; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CANCER SIZE; COLON CARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BISMUTH; COLONIC NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; ISOTOPE LABELING; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2542493831     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497804323071904     Document Type: Article

References (46)

1. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol 2000;10:73.
2. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: The coming of age of radiommunotherapy. Crit Rev Oncol Hematol 2001;39:195.
3. Larson SM. Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy. J Natl Cancer Inst 1991;83:1602.
4. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457.
5. Milenic DE, Roselli M, Mirzadeh S, et al. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biother Radiopharm 2001;16:133.
6. McDevitt MR, Barendswaard E, Ma D, et al. An alpha-particle-emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000; 60:6095.
7. Ruegg CL, Anderson-Berg WT, Brechbiel MW, et al. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 1990;50:4221.
8. Adams GP, Shaller CC, Chappell LL, et al. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol 2000;27:339.
9. Kennel SJ, Mirzadeh S, Eckelman WC, et al. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At. Radiat Res 2002;157:633.
10. 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional α-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res 2001;61:2804.
11. Hassfjell S, Brechbiel MW. The development of the alpha-particle-emitting radionuclides 212Bi and 213Bi, and their decay chain-related radionuclides, for therapeutic applications. Chem Rev 2001;101:2019.
12. Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood 2002;100:208.
13. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986;27:1490.
14. Kurtzman SH, Russo A, Mitchell JB, et al. 212Bismuth linked to an antipancreatic carcinoma antibody: Model for alpha-particle-emitter radioimmunotherapy. J Natl Cancer Inst 1988;80:449.
15. 225Ac. Radiochimica Acta 1997;79:141.
16. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233.
17. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999;40:1935.
18. Milenic DE. Radioimmunotherapy: Designer molecules to potentiate effective therapy. Semin Radiat Oncol 2000;10:139.
19. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55:3825.
20. Carrasquillo JA, Lang L, Whatley M, et al. Aminosyn II effectively blocks renal uptake of 18F-labeled antitac disulfide-stabilized Fv. Cancer Res 1998;58:2612.
21. DePalatis LR, Johnson KA, Kaplan DA. Combined immunohistochemical and autoradiographic analyses of antigen/antibody interactions in tumor xenograft models. Lab Invest 1991;65:111.
22. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363.
23. Yokota T, Milenic DE, Whitlow M, et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402.
24. Yokota T, Milenic DE, Whitlow M, et al. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 1993;53:3776.
25. Schott ME, Milenic DE, Yokota T, et al. Differential metabolic patterns of iodinated versus radiometalchelated anticarcinoma single-chin Fv molecules. Cancer Res 1992;52:6413.
26. 177Lu]alpha[2-(4-aminophenyl) ethyl]-1,4,7,10-tetra-aza-cyclodecane-1,4,7,10-tetraacetic acid-CC49 Fab radioimmunoconjugate. Cancer Res 1995;55:5288.
27. Slavin-Chiorini DC, Kashmiri SV, Lee HS, et al. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm 1997;12:305.
28. Forero A, Meredith RF, Khazaeli MB, et al. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 2003;18:751.
29. Brechbiel MW, Gansow OA. Synthesis of C-functionalized trans-cyclohexyldiethylene-triamine-penta-acetic acids for labeling of monoclonal antibodies with the bismuth-212 α-particle emitter. J Chem Soc Perkin Trans 1 1992;1173.
30. Huneke RB, Pippin CG, Squire RA, et al. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res 1992;52:5818.
31. Slavin-Chiorini DC, Kashmiri SV, Schlom J, et al. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 1995;555957S.
32. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 2002;29:431.
33. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. 1951;193:265.
34. Pippin CG, Parker TA, McMurry TJ, et al. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem 1992;3:342.
35. Fraker PJ, Speck JC, Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978;80:849.
36. Markwell MA. A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum. Anal Biochem 1982;125:427.
37. Tom BH, Rutzky LH, Jakstys MH. Human colonic adenocarcinoma cells. Establishment and description of a new cell line. In Vitro 1976;12:180.
38. Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha-particle-emitting radioimmunoconjugates. Acta Oncol 1996;35:373.
39. 211At-labeled monoclonal antibody MOv18. Anticancer Res 2000; 20:459.
40. Hartmann F, Horak EM, Garmestani K, et al. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res 1994;54:4362.
41. Nikula TK, McDevitt MR, Finn RD, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity, and chemistry. J Nucl Med 1999;40:166.
42. 177lutetium-labeled immunoconjugate. Cancer Res 1991;51:2889.
43. Siler K, Eggensperger D, Hand PH, et al. Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1). Biotechnol Ther 1993; 4:163.
44. 213Bi-An α-particle emitter. Nucl Med Biol 1998;25:241.
45. Thorpe PE, Derbyshire EJ. Targeting the vasculature of solid tumors. J Controlled Release 1997;48:277.
46. Xue LY, Butler NJ, Makrigiorgos GM, et al. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci 2002;99:13765.